Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...

Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at ...

Dutch life sciences investor Forbion has raised €2.3 billion across two new funds to finance about 30 biotech companies, ...

Oxford-based Sensible Biotechnologies has secured a $47 million (€42 million) financing package to scale a platform that ...

France’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of ...

Genmab and AbbVie's bispecific antibody epcoritamab, added to R-CHOP chemoimmunotherapy, cut the risk of progression or death by 51% in a Phase 3 trial in newly diagnosed diffuse large B-cell lymphoma ...

Australian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to ...

Genmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion ...

Boehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with ...

Novartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an ...

Swedish biotech Atrogi says its oral drug ATR-258 increased lower-extremity muscle power by about 13% after eight weeks in a ...

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us ...